^
Association details:
| Biomarker: | CDK4 amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A COMPREHENSIVE MODEL OF GENETIC-FEATURES PREDICTS OUTCOME OF PERSONALIZED ADJUVANT TREATMENT IN RESECTED EGFR-MUTANT STAGE II-IIIA NSCLC: RESULTS FROM A PHASE 3 TRIAL (CTONG 1104-ADJUVANT)
Published date:
09/29/2019
Excerpt:
TP53, NKX2-1, CDK4, MYC and RB1 were identified as predictive biomarkers...Specifically, gefitinib-favoring biomarkers include TP53 exon4/5 mutations (interaction HR [iHR] 0.33, 95% CI 0.12-0.93, p = 0.035), and copy number gain of NKX2-1 (iHR 0.26, 95% CI 0.098-0.68, p = 0.006), CDK4 (iHR 0.14, 95% CI 0.025-0.77, p = 0.024) and MYC (iHR 0.10, 95% CI 0.011-0.98, p = 0.048).
Secondary therapy:
cisplatin + vinorelbine tartrate
DOI:
10.1093/annonc/mdz258
Trial ID:
